• Home
  • Ministers
  • For Consumers
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • Ethical Issues
    • Gene Technology
    • Health Care Homes
    • Health products and medicines
    • Public and private healthcare
    • Industrial chemicals
    • Medicare
    • Mental Health
    • National Men's and Women's Health
    • National Rural Health Commissioner
    • Norfolk Island
    • Palliative Care
    • Pharmacy
    • Primary Care
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • Healthier Medicare
    • Travel Health Information
  • For Health Professionals
    • Aboriginal and Torres Strait Islander Health
    • Conditions and Diseases
    • Education and Prevention
    • Ethical Issues
    • Gene Technology
    • Genomics
    • Health Provider Compliance
    • Health products and medicines
    • Health Thesaurus
    • Health Workforce
    • Public and private healthcare
    • Healthier Medicare
    • Medicare
    • My Health Record
    • National Men's and Women's Health
    • Palliative Care
    • PBS Approved Suppliers
    • Regulation and Red Tape Reduction
    • Rural and Regional Health
    • Services
    • A Strong and Sustainable Medicare
    • Travel Health Information
  • About us
  • Media Centre
  • Programs & Campaigns
    • Agreements
    • Awards
    • eHealth
    • Programs & Initiatives
    • Campaign Certification Statements
  • Resources
    • Publications
    • Research & Statistics
    • CurrentIssues
  • Ageing & Aged Care
  • You are here:
  • Home /
  • For Consumers /
  • Education and Prevention /
  • Illicit Drugs /

Models of intervention and care for psychostimulant users, 2nd edition - monograph series no. 51

Section 2: Prevalence, effects and risks

Page last updated: April 2004

Chapter 2: Prevalence and patterns of psychostimulant use

Chapter 3: Pharmacology of psychostimulants

Chapter 4: Risks associated with psychostimulant use

  • previous page
  • next page
Listen
  • Table of contents
  • Section 1: Introduction
  • Section 2: Prevalence, effects and risks
    • Chapter 2: Prevalence and patterns of psychostimulant use
      • Introduction
      • Historical context
      • Global overview of trends in psychostimulant use
      • Prevalence and patterns of psychostimulant use in Australia
      • Prevalence and patterns of psychostimulant use among specific populations
      • Conclusion
    • Chapter 3: Pharmacology of psychostimulants
      • Introduction to the monoamine system
      • Pharmacology of amphetamines
      • Pharmacology of cocaine
      • Pharmacology of MDMA (ecstasy)
      • Psychostimulants and other drug use
      • Conclusion
    • Chapter 4: Risks associated with psychostimulant use
  • Section 3: Clinical considerations
    • Chapter 5: Psychosocial interventions
      • Survey data pertaining to treatment seeking
      • Clinical interventions
      • Conclusion
      • Summary of evidence
    • Chapter 6: Management of acute psychostimulant toxicity
      • Introduction
      • Assessment
      • Management of toxicity
      • Management of intoxication
      • Acute behavioural disturbances and psychoses
      • Serotonin toxicity
      • Cardiovascular emergencies
      • Cerebrovascular emergencies
      • Conclusion
      • Summary of evidence
    • Chapter 7: Psychostimulant withdrawal and detoxification
      • Introduction
      • The psychostimulant withdrawal syndrome
      • The cocaine withdrawal syndrome
      • The amphetamine withdrawal syndrome
      • Detoxification and withdrawal management
      • Assessment for detoxification
      • Settings for detoxification
      • Monitoring the withdrawal syndrome
      • The place of pharmacotherapies
      • Conclusion
      • Summary of evidence
      • Decision tree for the management of psychostimulant detoxification
    • Chapter 8: Pharmacological interventions
      • Introduction
      • Antidepressants
      • Dopamine agonists
      • Dopamine antagonists
      • Disulfiram
      • CNS stimulants
      • Modafinil
      • Vaccines
      • Calcium blockers
      • Opioid agonists and antagonists
      • Ecstasy
      • Alternative therapies
      • Conclusion
      • Summary of evidence
    • Chapter 9: Psychostimulants and young people
      • Introduction
      • Prevalence and patterns of psychostimulant use among young people
      • Risk, protection, transitions and connectedness
      • Adverse effects
      • Prevention and population-based interventions
      • Assessment
      • Management and treatment
      • Treatment of young people with alcohol and other drug problems
      • Specific treatment interventions
      • Conclusion
      • Summary of evidence
    • Chapter 10: The psychiatric comorbidity of psychostimulant use
      • Overview
      • Prevalence of comorbid psychiatric conditions and substance use
      • Psychotic disorders among psychostimulant users
      • Affective and mood disorders in psychostimulant users
      • Assessment of comborbidity in psychostimulant users
      • Psychosocial approaches to comorbid psychiatric disorders and psychostimulant use
      • Conclusion
    • Chapter 11: Psychostimulant use in pregnancy and lactation
      • Introduction
      • Part I: Pathophysiological considerations
      • Part II: Profile of individual drugs
      • Part III: Management of the pregnant and lactating psychostimulant user
      • Conclusion
    • Chapter 12: Clinical recommendations
    • Chapter 13: Future research directions
  • References
  • Glossary of terms
  • List of abbreviations

Popular

    • Feedback
    Provide feedbackIf you would like a response please complete our enquiries form.


    Comments will be used to improve web content and will not be responded to.

    Real person check

    This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


    Privacy statement

    Your feedback has been submitted

    Thank you for taking the time to provide feedback. It will be used to make improvements to this website.